Investors

Overview

Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Recent News

DateTitle
05/14/18U.S. Food and Drug Administration Accepts and Acknowledges Coherus BioSciences Biologics License Application of CHS-1701 (Pegfilgrastim Biosimilar Candidate) for Review
REDWOOD CITY, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced the U.S. Food and Drug Administration (FDA) has accepted and acknowledged for review the re-submission of the biologics license application (BLA) for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate.  In the communication, FDA indicated that they consider the resubmission a complete response to their June 9, 2017 action letter.  FDA provided a biosimilar user fee act (BSUFA... 
05/10/18Coherus BioSciences Reports Corporate Highlights and First Quarter 2018 Financial Results
REDWOOD CITY, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reviewed corporate highlights and reported financial results for the quarter ended March 31, 2018.   First Quarter 2018 Corporate Highlights Include: Oncology therapeutic franchise: CHS-1701 (pegfilgrastim (Neulasta®) biosimilar candidate) Announced on March 26, 2018, that Judge Stark of the United States District Court for the District of Delaware adopted Magistrate Judge Bur... 
05/10/18Coherus BioSciences Appoints Samuel Nussbaum, M.D. to Board of Directors
REDWOOD CITY, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced the appointment of Samuel Nussbaum, M.D. to its Board of Directors.   “We are thrilled to have a health care policy and payer expert of Dr. Nussbaum’s stature join the Coherus Board of Directors. Recent introductions of therapeutic biologics and biosimilars to the U.S. market, have highlighted the importance of a robust market access strategy and execution. Dr. Nussbaum’s distingu... 
05/03/18Coherus BioSciences Re-Submits Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
REDWOOD CITY, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced the re-submission of its biologics license application (BLA) for CHS-1701, a pegfilgrastim (Neulasta®) biosimilar candidate, to the U.S. FDA under the 351(k) pathway. The BLA is supported by similarity data from analytical, pharmacokinetic, pharmacodynamics, and immunogenicity studies comparing CHS-1701 and Neulasta and integrates new immunogenicity data obtained from using a more... 
View All

Upcoming Events

There are currently no events scheduled.
View All

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Coherus Biosciences Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

CHRS (Common Stock)

ExchangeNASDAQ (US Dollar)
Price$15.50
Change (%) Stock is Down 0.45 (2.82%)
Volume492,562
Data as of 05/18/18 4:00 p.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Financial Tear SheetFinancial Tear Sheet